References
- Pearce EJ, Everts B. Dendritic cell metabolism. Nat Rev Immunol. 2015;15(1):18–29.
- Constantino J, Gomes C, Falcao A, et al. Dendritic cell-based immunotherapy: a basic review and recent advances. Immunol Res. 2017;65:798–810.
- Wilson NS, El-Sukkari D, Belz GT, et al. Most lymphoid organ dendritic cell types are phenotypically and functionally immature. Blood. 2003;102:2187.
- Dudek AM, Martin S, Garg AD, et al. Immature, semi-mature, and fully mature dendritic cells: toward a DC-cancer cells interface that augments anticancer immunity. Front Immunol. 2013;4:438.
- Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol. 2006;6:476–483.
- Vega-Ramos J, Roquilly A, Asehnoune K, et al. Modulation of dendritic cell antigen presentation by pathogens, tissue damage and secondary inflammatory signals. Curr Opin Pharmacol. 2014;17:64–70.
- Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol. 2010;108:111–165.
- Gardner L, Moffett A. Dendritic cells in the human decidua. Biol Reprod. 2003;69:1438–1446.
- Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood. 2006;108:1435–1440.
- Nicola NA, Babon JJ. Leukemia inhibitory factor (LIF). Cytokine Growth Factor Rev. 2015;26:533–544.
- Linker RA, Kruse N, Israel S, et al. Leukemia inhibitory factor deficiency modulates the immune response and limits autoimmune demyelination: a new role for neurotrophic cytokines in neuroinflammation. J Immunol. 2008;180:2204–2213.
- Hilton DJ, Nicola NA, Metcalf D. Distribution and comparison of receptors for leukemia inhibitory factor on murine hemopoietic and hepatic cells. J Cell Physiol. 1991;146:207–215.
- Metcalf D. The unsolved enigmas of leukemia inhibitory factor. Stem Cells (Dayton, Ohio). 2003;21:5–14.
- Nasef A, Mazurier C, Bouchet S, et al. Leukemia inhibitory factor: role in human mesenchymal stem cells mediated immunosuppression. Cell Immunol. 2008;253:16–22.
- Zhu M, Oishi K, Chul Lee S, et al. Studies using leukemia inhibitory factor (LIF) knockout mice and a LIF adenoviral vector demonstrate a key anti-inflammatory role for this cytokine in cutaneous inflammation. J Immunol. 2001;166:2049.
- Yu H, Yue X, Zhao Y, et al. LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nat Commun. 2014;5:5218.
- Kuphal S, Wallner S, Bosserhoff AK. Impact of LIF (leukemia inhibitory factor) expression in malignant melanoma. Exp Mol Pathol. 2013;95:156–165.
- Metcalfe SM. LIF in the regulation of T-cell fate and as a potential therapeutic. Genes Immun. 2011;12:157–168.
- Kimber SJ. Leukaemia inhibitory factor in implantation and uterine biology. Reproduction. 2005;130:131–145.
- Weber MA, Schnyder-Candrian S, Schnyder B, et al. Endogenous leukemia inhibitory factor attenuates endotoxin response. Lab Invest. 2005;85:276–284.
- Levy YA, Mausner-Fainberg K, Vaknin-Dembinsky A, et al. Dysregulated production of leukemia inhibitory factor in immune cells of relapsing remitting multiple sclerosis patients. J Neuroimmunol. 2015;278:85–89.
- Vela L, Caballero I, Fang L, et al. Discovery of enhancers of the secretion of leukemia inhibitory factor for the treatment of multiple sclerosis. J Biomol Screen. 2016;21:437–445.
- Cao W, Yang Y, Wang Z, et al. Leukemia inhibitory factor inhibits T helper 17 cell differentiation and confers treatment effects of neural progenitor cell therapy in autoimmune disease. Immunity. 2011;35:273–284.
- Metcalfe SM. Axotrophin and leukaemia inhibitory factor (LIF) in transplantation tolerance. Philos Trans R Soc Lond B Biol Sci. 2005;360:1687–1694.
- Metcalfe SM, Watson TJ, Shurey S, et al. Leukemia inhibitory factor is linked to regulatory transplantation tolerance. Transplantation. 2005;79:726–730.
- Akita S, Ishihara H, Mohammad Abdur R, et al. Leukemia inhibitory factor gene improves skin allograft survival in the mouse model. Transplantation. 2000;70:1026–1031.
- Dashti A, Ebrahimi M, Hadjati J, et al. Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses. Cancer Lett. 2016;374:175–185.
- Kobie JJ, Wu RS, Kurt RA, et al. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res. 2003;63:1860–1864.
- Liu K, Nussenzweig MC. Origin and development of dendritic cells. Immunol Rev. 2010;234:45–54.
- Wetzler M, Talpaz M, Lowe DG, et al. Constitutive expression of leukemia inhibitory factor RNA by human bone marrow stromal cells and modulation by IL-1, TNF-alpha, and TGF-beta. Exp Hematol. 1991;19:347–351.
- Escary JL, Perreau J, Dumenil D, et al. Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation. Nature. 1993;363:361–364.
- Le PT, Lazorick S, Whichard LP, et al. Human thymic epithelial cells produce IL-6, granulocyte–monocyte–CSF, and leukemia inhibitory factor. J Immunol (Baltimore, MD: 1950). 1990;145(10):3310–3315.
- Keller JR, Gooya JM, Ruscetti FW. Direct synergistic effects of leukemia inhibitory factor on hematopoietic progenitor cell growth: comparison with other hematopoietins that use the gp130 receptor subunit. Blood. 1996;88:863–869.
- Mathieu ME, Saucourt C, Mournetas V, et al. LIF-dependent signaling: new pieces in the Lego. Stem Cell Rev Rep. 2012;8:1–15.
- Liu K, Victora GD, Schwickert TA, et al. In vivo analysis of dendritic cell development and homeostasis. Science. 2009;324:392–397.
- Merad M, Manz MG, Karsunky H, et al. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol. 2002;3:1135–1141.
- Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol. 2004;4:24–34.
- Manicassamy S, Pulendran B. Dendritic cell control of tolerogenic responses. Immunol Rev. 2011;241:206–227.
- Steinbrink K, Wolfl M, Jonuleit H, et al. Induction of tolerance by IL-10-treated dendritic cells. J Immunol (Baltimore, MD: 1950). 1997;159:4772–4780.
- Song SS, Yuan PF, Chen JY, et al. TGF-beta favors bone marrow-derived dendritic cells to acquire tolerogenic properties. Immunol Investig. 2014;43:360–369.
- Piemonti L, Monti P, Allavena P, et al. Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol (Baltimore, MD: 1950). 1999;162:6473–6481.
- Penna G, Adorini L. 1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol (Baltimore, MD: 1950). 2000;164:2405–2411.
- Eftekharian MM, Zarnani AH, Moazzeni SM. In vivo effects of calcitriol on phenotypic and functional properties of dendritic cells. Iran J Immunol. 2010;7:74–82.
- Hendriks JJ, Slaets H, Carmans S, et al. Leukemia inhibitory factor modulates production of inflammatory mediators and myelin phagocytosis by macrophages. J Neuroimmunol. 2008;204:52–57.
- Gao W, Thompson L, Zhou Q, et al. Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. Cell Cycle (Georgetown, TX). 2009;8:1444–1450.
- Mahic M, Kalland ME, Aandahl EM, et al. Human naturally occurring and adaptive regulatory T cells secrete high levels of leukaemia inhibitory factor upon activation. Scand J Immunol. 2008;68:391–396.
- Duluc D, Delneste Y, Tan F, et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood. 2007;110:4319–4330.
- Chen F, Hou M, Ye F, et al. Ovarian cancer cells induce peripheral mature dendritic cells to differentiate into macrophagelike cells in vitro. Int J Gynecol Cancer. 2009;19:1487–1493.
- Laouar Y, Welte T, Fu XY, et al. STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity. 2003;19:903–912.
- Park SJ, Nakagawa T, Kitamura H, et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol (Baltimore, MD: 1950). 2004;173:3844–3854.
- Xie J, Qian J, Wang S, et al. Novel and detrimental effects of lipopolysaccharide on in vitro generation of immature dendritic cells: involvement of mitogen-activated protein kinase p38. J Immunol (Baltimore, MD: 1950). 2003;171:4792–4800.
- Nakahara T, Moroi Y, Uchi H, et al. Differential role of MAPK signaling in human dendritic cell maturation and Th1/Th2 engagement. J Dermatol Sci. 2006;42:1–11.